SEARCH OUR PAGES

Auto-Immunity & Inflammation Platform

Auto-Immunity & Inflammation Platform

OSE Immunotherapeutics’ auto-immunity & inflammation platform consists of two clinical-stage programs with promising candidates focusing on two different pathways:
– the CD28 pathway with FR104
– the IL-7 pathway with OSE-127. OSE-127 is partnered with Servier for its development in ulcerative colitis and Sjögren’s syndrome.

For inflammation, OSE Immunotherapeutics is developing OSE-230, an agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), known to modulate inflammation. OSE-230 is based on a disruptive concept in the inflammation space – using an antibody-based therapeutic to drive the resolution of the inflammation process rather than targeting and blocking pro-inflammatory signals.

Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Auto-Immunity & Inflammation Platform
OSE-127
IL7-R Antagonist
UC; Sjögren
On-going in UC; planned in Sjögren
FR104
CD28 Antagonist
Auto-immune diseases & Transplantation
Tx (Veloxis): Phase 1 status
AID: Phase 2 status
OSE-230
Anti-ChemR23 Agonist
Resolution of inflammation
Ongoing

Platform

  • Target Modality IL7-R Antagonist
  • Indication UC; Sjögren
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 On-going in UC; planned in Sjögren
  • Phase 3
  • Partners
  • Target Modality CD28 Antagonist
  • Indication Auto-immune diseases & Transplantation
  • Pre-Clinical POC
  • Phase 1 Tx (Veloxis): Phase 1 status
  • Phase 2 AID: Phase 2 status
  • Phase 3
  • Partners
  • Target Modality Anti-ChemR23 Agonist
  • Indication Resolution of inflammation
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • OSE-127

    +
  • FR104

    +
  • OSE-230

    +